Valuation: Mymetics Corp

Market Cap 439K 385K 358K 329K 618K 42.25M 627K 4.26M 1.66M 20.77M 1.65M 1.61M 71.82M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 63.35M 58.91M 54.06M 102M 6.95B 103M 700M 273M 3.41B 271M 265M 11.81B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
-11.43%+44.21% - - 45
-1.92%-1.57%+48.70%+84.37% 55.92B
+0.93%+6.97%+62.83%+67.97% 56.67B
-2.21%-1.57%-21.41%-15.87% 23.28B
-0.68%-1.59%+2.98%+421.02% 23.28B
-0.36%-0.56%+36.00%-3.93% 20.54B
-1.34%+0.51%+25.02%-30.27% 17.78B
-1.44%-1.63%+37.07%+589.93% 15.9B
-1.30%-9.92%+160.67%+284.37% 14.64B
-0.06%-0.41%+24.34%+179.99% 13.99B
Average -1.98%+0.47%+41.80%+175.29% 26.89B
Weighted average by Cap. -0.81%+1.47%+42.65%+138.19%

Financials

2021 2022
Net sales 430K 378K 351K 322K 606K 41.41M 615K 4.17M 1.63M 20.36M 1.61M 1.58M 70.39M 1.03M 903K 840K 771K 1.45M 99M 1.47M 9.97M 3.9M 48.67M 3.86M 3.78M 168M
Net income -4.73M -4.15M -3.86M -3.55M -6.66M -456M -6.76M -45.88M -17.92M -224M -17.76M -17.37M -774M -4.8M -4.22M -3.92M -3.6M -6.77M -463M -6.87M -46.6M -18.21M -227M -18.04M -17.65M -787M
Net Debt 67.1M 58.93M 54.81M 50.29M 94.5M 6.46B 95.95M 651M 254M 3.18B 252M 246M 10.98B 71.68M 62.96M 58.55M 53.73M 101M 6.9B 103M 695M 272M 3.39B 269M 263M 11.73B
Logo Mymetics Corp
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-